This paper appears in the following:
- No Toxicity in Tau’s Tangles?
- SfN: Return of the Other—Tau Is Back, Part 1
- Chicago: Tau and α-Synuclein Oligomers Follow Aβ Footsteps
- Las Vegas: Are Frontotemporal Dementia Models Fit for Pharma?
- San Francisco: Tau—Time to Shine as Therapeutic Target?
- The Many Faces of LRRK2
- Making It Stick—Tau Toxicity Linked to Aggregation Propensity
- Tau Timing: New Findings on Disease Progression, Clearance
- Heart and Brain—Oligomers Forge New Connection